Method of evaluating myelosuppressive state
AssigneeCenter for Molecular Medicine and Immunology
InventorsRosalyn D. Blumenthal, Walter Lew, Malik Juweid, Rita Alisauskas, Zhiliang Ying, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
Claims6
A kit for assessing myclosuppressive state of a patient, comprising a cytokine-specific detection reagent, wherein said cytokines-specific detection reagent comprises antibodies to cytokines selected from the group consisting of fms-like tyrosine-kinase 3 ligand (FLT3-L), tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β), and said reagent is adapted to detect a threshold level of at least one said cytoline, said threshold correlating with said state, and instructions for assessing said myelosuppressive state of a patient,
- wherein said threshold level of FLT3-L is a maximum threshold level, wherein said maximum threshold level is at least about 135 pg/ml of said FLT3-L in plasma;
- and
- wherein said threshold level of TGF-β and TNF-α is a minimum threshold level, wherein said mum threshold level is at most about 0.5 pg/ml of plasma for TNF-α, and about 15 pg/ml of plasma for TGF-β.
Dependencies are inferred from the claim text.